drugset

drugset / Trial / NCT02439190

CV004-007 Thrombosis Chamber Study

NCT02439190 ↗

Phase 1 Completed 42 enrolled Bristol-Myers Squibb

RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to determine whether BMS-986120, aspirin, or aspirin and clopidogrel decrease blood clotting.

Timeline

Start: 2015-09
Primary completion: 2016-03
Completion: 2016-03

Publications

Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, Gray TJ, Connell S, Garonzik S, Ma X, Yang J, Newby DE. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. doi: 10.1161/ATVBAHA.117.310104. Epub 2017 Dec 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aspirin	Small molecule	600 mg	Oral
Comparator	BMS-986120	Unknown	60 mg	Oral
Comparator	Clopidogrel	Small molecule	600 mg	Oral

Indications